Vol. 2 No. 2 (2022)
Reimbursement Reviews

Estradiol (Imvexxy)

Published February 24, 2022

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses estradiol (Imvexxy), 4 mcg and 10 mcg, vaginal inserts.
  • Indication: For the treatment of postmenopausal moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy.